Amgen Inc. Stock price

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 02:29:56 24/02/2024 am IST 5-day change 1st Jan Change
289.2 USD +1.42% Intraday chart for Amgen Inc. +1.95% +0.42%
Sales 2024 * 32.88B 2,724B Sales 2025 * 34.06B 2,821B Capitalization 155B 12,838B
Net income 2024 * 6.19B 512B Net income 2025 * 7.43B 615B EV / Sales 2024 * 6.16 x
Net Debt 2024 * 47.48B 3,933B Net Debt 2025 * 42.05B 3,483B EV / Sales 2025 * 5.79 x
P/E ratio 2024 *
25 x
P/E ratio 2025 *
19.2 x
Employees 26,700
Yield 2024 *
3.2%
Yield 2025 *
3.46%
Free-Float 99.63%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Amgen Inc.

1 day+1.42%
1 week+1.95%
Current month-7.96%
1 month-5.33%
3 months+8.95%
6 months+12.71%
Current year+0.42%
More quotes
1 week
280.55
Extreme 280.55
292.24
1 month
280.55
Extreme 280.55
329.72
Current year
280.55
Extreme 280.55
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
108.20
Extreme 108.2
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 01/06/01
Director of Finance/CFO 65 23/19/23
Chief Tech/Sci/R&D Officer 61 01/05/01
Members of the board TitleAgeSince
Director/Board Member 67 03/17/03
Director/Board Member 68 14/16/14
Director/Board Member 75 17/14/17
More insiders
Date Price Change Volume
23/24/23 289.2 +1.40% 2,462,555
22/24/22 285.2 +0.61% 2,992,891
21/24/21 283.5 -0.02% 1,934,490
20/24/20 283.5 -0.07% 3,402,126
16/24/16 283.7 -1.86% 3,596,798

Delayed Quote Nasdaq, February 24, 2024 at 02:29 am IST

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.6% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
289.2 USD
Average target price
303.6 USD
Spread / Average Target
+5.00%
Consensus
1st Jan change Capi.
+0.42% 155 B $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer